Nimble Therapeutics

Madison, United States Founded: 2019 • Age: 7 yrs Acquired By AbbVie
Combinatorial chemistry services for peptide-based drug discovery are provided.
Annual revenue - Latest available
Total funding $10.0M 1 rounds
Employees 24 Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Nimble Therapeutics

Nimble Therapeutics is a company based in Madison (United States) founded in 2019 was acquired by AbbVie in December 2024. Nimble Therapeutics has raised $10 million across 1 funding round from investors including AbbVie and Telegraph Hill Partners. The company has 24 employees as of December 31, 2021. Nimble Therapeutics operates in a competitive market with competitors including Aqemia, NTxBio, Applied BioMath, Enveda and IMIDomics, among others.

  • Headquarter Madison, United States
  • Employees 24 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Nimble Therapeutics, Inc
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $10 M (USD)

    in 1 rounds

  • Latest Funding Round
    $10 M (USD), Series A

    Apr 30, 2019

  • Investors
    AbbVie

    & 1 more

  • Employee Count
    24

    as on Dec 31, 2021

  • Acquired by
    AbbVie

    (Dec 13, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Nimble Therapeutics

Headcount 10-50
Employee Profiles 12
Board Members and Advisors 3
Employee Profiles
People
Jigar Patel
Founder & CEO
People
Andrew Wagner
Director, Software & Engineering
People
Brad Garcia
VP, Corporate Development
People
Eric Dauenhauer
Principal Engineer

Unlock access to complete

Funding Insights of Nimble Therapeutics

Nimble Therapeutics has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series A round of $10 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Nimble Therapeutics

Nimble Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie and Telegraph Hill Partners.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm focused on life science, medical device and healthcare companies
Locked Locked Locked
Biopharmaceutical research and drug development are conducted globally by AbbVie.
Locked Locked Locked
Premium access

Investor details for Nimble Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Nimble Therapeutics

Investments
Premium access

Investment portfolio details for Nimble Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Nimble Therapeutics

Premium access

Detailed financials for Nimble Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Nimble Therapeutics Comparisons

Nimble Therapeutics Primary company
Description
Combinatorial chemistry services for peptide-based drug disc...
Location
Madison, United States
Founded Year
2019
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
24
As of 2021
Premium access

Peer comparison for Nimble Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Nimble Therapeutics

Nimble Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aqemia, NTxBio, Applied BioMath, Enveda and IMIDomics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutic molecules are discovered through AI and quantum physics integration.
Locked Locked Locked
Provider of bio informatics platform to develops biologics and therapeutics
Locked Locked Locked
Systems biology and pharmacology modeling services to aid drug discovery and development
Locked Locked Locked
Provider of AI-based platform to decipher the chemistry of nature and develop new medicines
Locked Locked Locked
Precision medicines for immune-mediated inflammatory diseases are developed.
Premium access

Detailed competitors of Nimble Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Nimble Therapeutics

Premium access

Complete news archive for Nimble Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nimble Therapeutics

Nimble Therapeutics was founded in 2019.

Nimble Therapeutics is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.

Nimble Therapeutics is a funded company, having raised a total of $10M across 1 funding round to date.

As of Dec 31, 2021, the latest employee count at Nimble Therapeutics is 24.

Nimble Therapeutics was founded in 2019 in Madison, United States, within the biotechnology sector. Drug discovery services centered on combinatorial chemistry are offered, with a focus on peptide technologies. A chemical synthesis platform has been developed to facilitate the creation and evaluation of various peptides, including scaffolded natural and modified macrocyclic peptidomimetics. Operations emphasize efficient screening processes for potential therapeutic compounds in the pharmaceutical industry.

Nimble Therapeutics's top competitors include Aqemia, NTxBio and Enveda.

Nimble Therapeutics has 2 investors. Key investors include AbbVie, and Telegraph Hill Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available